Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer

In vitro and in vivo studies

Giovanni Vitale, Giovanni Lupoli, Rosario Guarrasi, Annamaria Colao, Alessandra Dicitore, Germano Gaudenzi, Gabriella Misso, Maria Castellano, Raffaele Addeo, Gaetano Facchini, Salvatore Del Prete, Michele Caraglia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (MTC). Objective: We investigated in vitro and in vivo a new strategy for the therapy of MTC, combining human recombinant IL-2 with lanreotide (LAN), a somatostatin analog. Methods: The in vitro effects of LAN on the sensitivity of TT cells, a MTC cell line, to IL-2-stimulated human peripheral blood mononuclear cells were determined by a lactate dehydrogenase release assay. In addition, we evaluated the toxicity, the effects on quality of life, and the antitumor activity of sc low-dose IL-2 in combination with LAN (90 mg every 28 days) in a series of 6 patients with symptomatic and advanced MTC. Results: The cytotoxicity of IL-2-activated peripheral blood mononuclear cells was significantly increased in TT cells treated with LAN or LAN plus IL-2 compared with that in TT cells without treatment. The therapy was well tolerated, and a statistically significant improvement of quality of life was observed in patients treated with the combination of LAN and IL-2. After 6 months of therapy, partial response and stable disease have been recorded in 2 and 3 patients, respectively, with a significant decrease in calcitonin levels in 3 patients. Conclusions: Both in vitro and in vivo evidence suggests that the combination of LAN and IL-2 may have a role in the management of advanced and symptomatic MTC. However, these preliminary data require further validation in larger randomized trials.

Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Interleukin-2
Therapeutics
Blood Cells
Blood
Quality of Life
Calcitonin
Cytotoxicity
lanreotide
In Vitro Techniques
Medullary Thyroid cancer
Somatostatin
L-Lactate Dehydrogenase
Toxicity
Assays
Cells
Cell Line

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer : In vitro and in vivo studies. / Vitale, Giovanni; Lupoli, Giovanni; Guarrasi, Rosario; Colao, Annamaria; Dicitore, Alessandra; Gaudenzi, Germano; Misso, Gabriella; Castellano, Maria; Addeo, Raffaele; Facchini, Gaetano; Del Prete, Salvatore; Caraglia, Michele.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 10, 10.2013.

Research output: Contribution to journalArticle

Vitale, Giovanni ; Lupoli, Giovanni ; Guarrasi, Rosario ; Colao, Annamaria ; Dicitore, Alessandra ; Gaudenzi, Germano ; Misso, Gabriella ; Castellano, Maria ; Addeo, Raffaele ; Facchini, Gaetano ; Del Prete, Salvatore ; Caraglia, Michele. / Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer : In vitro and in vivo studies. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 10.
@article{66d551463a9b47928c9c6b49db16e56d,
title = "Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: In vitro and in vivo studies",
abstract = "Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (MTC). Objective: We investigated in vitro and in vivo a new strategy for the therapy of MTC, combining human recombinant IL-2 with lanreotide (LAN), a somatostatin analog. Methods: The in vitro effects of LAN on the sensitivity of TT cells, a MTC cell line, to IL-2-stimulated human peripheral blood mononuclear cells were determined by a lactate dehydrogenase release assay. In addition, we evaluated the toxicity, the effects on quality of life, and the antitumor activity of sc low-dose IL-2 in combination with LAN (90 mg every 28 days) in a series of 6 patients with symptomatic and advanced MTC. Results: The cytotoxicity of IL-2-activated peripheral blood mononuclear cells was significantly increased in TT cells treated with LAN or LAN plus IL-2 compared with that in TT cells without treatment. The therapy was well tolerated, and a statistically significant improvement of quality of life was observed in patients treated with the combination of LAN and IL-2. After 6 months of therapy, partial response and stable disease have been recorded in 2 and 3 patients, respectively, with a significant decrease in calcitonin levels in 3 patients. Conclusions: Both in vitro and in vivo evidence suggests that the combination of LAN and IL-2 may have a role in the management of advanced and symptomatic MTC. However, these preliminary data require further validation in larger randomized trials.",
author = "Giovanni Vitale and Giovanni Lupoli and Rosario Guarrasi and Annamaria Colao and Alessandra Dicitore and Germano Gaudenzi and Gabriella Misso and Maria Castellano and Raffaele Addeo and Gaetano Facchini and {Del Prete}, Salvatore and Michele Caraglia",
year = "2013",
month = "10",
doi = "10.1210/jc.2013-1443",
language = "English",
volume = "98",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer

T2 - In vitro and in vivo studies

AU - Vitale, Giovanni

AU - Lupoli, Giovanni

AU - Guarrasi, Rosario

AU - Colao, Annamaria

AU - Dicitore, Alessandra

AU - Gaudenzi, Germano

AU - Misso, Gabriella

AU - Castellano, Maria

AU - Addeo, Raffaele

AU - Facchini, Gaetano

AU - Del Prete, Salvatore

AU - Caraglia, Michele

PY - 2013/10

Y1 - 2013/10

N2 - Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (MTC). Objective: We investigated in vitro and in vivo a new strategy for the therapy of MTC, combining human recombinant IL-2 with lanreotide (LAN), a somatostatin analog. Methods: The in vitro effects of LAN on the sensitivity of TT cells, a MTC cell line, to IL-2-stimulated human peripheral blood mononuclear cells were determined by a lactate dehydrogenase release assay. In addition, we evaluated the toxicity, the effects on quality of life, and the antitumor activity of sc low-dose IL-2 in combination with LAN (90 mg every 28 days) in a series of 6 patients with symptomatic and advanced MTC. Results: The cytotoxicity of IL-2-activated peripheral blood mononuclear cells was significantly increased in TT cells treated with LAN or LAN plus IL-2 compared with that in TT cells without treatment. The therapy was well tolerated, and a statistically significant improvement of quality of life was observed in patients treated with the combination of LAN and IL-2. After 6 months of therapy, partial response and stable disease have been recorded in 2 and 3 patients, respectively, with a significant decrease in calcitonin levels in 3 patients. Conclusions: Both in vitro and in vivo evidence suggests that the combination of LAN and IL-2 may have a role in the management of advanced and symptomatic MTC. However, these preliminary data require further validation in larger randomized trials.

AB - Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (MTC). Objective: We investigated in vitro and in vivo a new strategy for the therapy of MTC, combining human recombinant IL-2 with lanreotide (LAN), a somatostatin analog. Methods: The in vitro effects of LAN on the sensitivity of TT cells, a MTC cell line, to IL-2-stimulated human peripheral blood mononuclear cells were determined by a lactate dehydrogenase release assay. In addition, we evaluated the toxicity, the effects on quality of life, and the antitumor activity of sc low-dose IL-2 in combination with LAN (90 mg every 28 days) in a series of 6 patients with symptomatic and advanced MTC. Results: The cytotoxicity of IL-2-activated peripheral blood mononuclear cells was significantly increased in TT cells treated with LAN or LAN plus IL-2 compared with that in TT cells without treatment. The therapy was well tolerated, and a statistically significant improvement of quality of life was observed in patients treated with the combination of LAN and IL-2. After 6 months of therapy, partial response and stable disease have been recorded in 2 and 3 patients, respectively, with a significant decrease in calcitonin levels in 3 patients. Conclusions: Both in vitro and in vivo evidence suggests that the combination of LAN and IL-2 may have a role in the management of advanced and symptomatic MTC. However, these preliminary data require further validation in larger randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=84885212161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885212161&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-1443

DO - 10.1210/jc.2013-1443

M3 - Article

VL - 98

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -